FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona Therapeutics has secured US Food and Drug Administration (FDA) approval for Zevaskyn (prademagene zamikeracel), a gene-corrected cell therapy designed…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a news and features reporter for Pharmaceutical Technology. Jenna holds a BSc in Biochemistry and has interests in rare diseases, gene therapies, and oncology. Contact Jenna
-
-
AstraZeneca CEO calls for increased European investment in pharma
AstraZeneca CEO Pascal Soriot has urged European governments to increase investment in pharmaceutical innovation, warning of a growing imbalance between…
-
Biohaven secures $600m financing as it awaits FDA prodrug decision
Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with non-dilutive capital…
-
France halts Valneva’s chikungunya vaccine use in seniors
French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after serious…
-
Merck KGaA strikes $3.9bn deal for SpringWorks
Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire…
-
Merck KGaA nears $3.5bn deal for SpringWorks
Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an…
-
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and…
-
MSD’s Gardasil sales slide further due to China constraints
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus…
-
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to…
-
Veraxa to go public in $1.6bn SPAC deal with Voyager
Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp,…